Valuation
- Market cap
- 249,208,000
- Revenue TTM
- $0
- Net income TTM
- $-16,780,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,996,000
- Avg volume
- 2,543,528
- Day's range
- $1.43 – $1.48
- Shares out
- 174,271,000
- Stochastic %K
- 31%
- Beta
- 1.61
- Analysts
- Strong Sell
- Price target
- $10.40
Company profile
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease...
Show more
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 704 4900
- Website
- https://www.palisadebio.com
- Address
- 4600 South Syracuse Street, Suite 900, Denver, United States
Latest news
No headlines yet.
